Methoxy polyethylene glycol-epoetin beta
- Generic Name
- Methoxy polyethylene glycol-epoetin beta
- Brand Names
- Mircera
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 677324-53-7
- Unique Ingredient Identifier
- LR3UXN0193
- Background
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
- Indication
For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Chronic Renal Anemia
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT00550680
MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT00545571
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT00462384
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
Phase 3
Terminated
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT00454246
A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Phase 3
Terminated
- Conditions
- Anemia
- Interventions
- Drug: Epoetin alfaDrug: methoxy polyethylene glycol-epoetin beta
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 260
- Registration Number
- NCT00422513
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1228
- Registration Number
- NCT00090753
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath